Literature DB >> 22203673

Engineering upper hinge improves stability and effector function of a human IgG1.

Boxu Yan1, Daniel Boyd, Timothy Kaschak, Joni Tsukuda, Amy Shen, Yuwen Lin, Shan Chung, Priyanka Gupta, Amrita Kamath, Anne Wong, Jean-Michel Vernes, Gloria Y Meng, Klara Totpal, Gabriele Schaefer, Guoying Jiang, Bartek Nogal, Craig Emery, Martin Vanderlaan, Paul Carter, Reed Harris, Ashraf Amanullah.   

Abstract

Upper hinge is vulnerable to radical attacks that result in breakage of the heavy-light chain linkage and cleavage of the hinge of an IgG1. To further explore mechanisms responsible for the radical induced hinge degradation, nine mutants were designed to determine the roles that the upper hinge Asp and His play in the radical reactions. The observation that none of these substitutions could inhibit the breakage of the heavy-light chain linkage suggests that the breakage may result from electron transfer from Cys(231) directly to the heavy-light chain linkage upon radical attacks, and implies a pathway separate from His(229)-mediated hinge cleavage. On the other hand, the substitution of His(229) with Tyr showed promising advantages over the native antibody and other substitutions in improving the stability and function of the IgG1. This substitution inhibited the hinge cleavage by 98% and suggests that the redox active nature of Tyr did not enable it to replicate the ability of His to facilitate radical induced degradation. We propose that the lower redox potential of Tyr, a residue that may be the ultimate sink for oxidizing equivalents in proteins, is responsible for the inhibition. More importantly, the substitution increased the antibody's binding to FcγRIII receptors by 2-3-fold, and improved ADCC activity by 2-fold, while maintaining a similar pharmacokinetic profile with respect to the wild type. Implications of these observations for antibody engineering and development are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203673      PMCID: PMC3325591          DOI: 10.1074/jbc.M111.311811

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  Post-translational modifications in the context of therapeutic proteins.

Authors:  Gary Walsh; Roy Jefferis
Journal:  Nat Biotechnol       Date:  2006-10       Impact factor: 54.908

2.  Development trends for therapeutic antibody fragments.

Authors:  Aaron L Nelson; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

3.  Toward biosimilar monoclonal antibodies.

Authors:  Christian K Schneider; Ulrich Kalinke
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908

4.  Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

Authors:  Amita Datta-Mannan; Derrick R Witcher; Ying Tang; Jeffry Watkins; Victor J Wroblewski
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

5.  Site-specific insertion of 3-aminotyrosine into subunit alpha2 of E. coli ribonucleotide reductase: direct evidence for involvement of Y730 and Y731 in radical propagation.

Authors:  Mohammad R Seyedsayamdost; Jianming Xie; Clement T Y Chan; Peter G Schultz; JoAnne Stubbe
Journal:  J Am Chem Soc       Date:  2007-11-09       Impact factor: 15.419

6.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

7.  Structural characterization of a mutated, ADCC-enhanced human Fc fragment.

Authors:  Vaheh Oganesyan; Melissa M Damschroder; William Leach; Herren Wu; William F Dall'Acqua
Journal:  Mol Immunol       Date:  2008-04       Impact factor: 4.407

Review 8.  Proton-coupled electron transfer in biology: results from synergistic studies in natural and model systems.

Authors:  Steven Y Reece; Daniel G Nocera
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

Review 9.  FcRn: the neonatal Fc receptor comes of age.

Authors:  Derry C Roopenian; Shreeram Akilesh
Journal:  Nat Rev Immunol       Date:  2007-08-17       Impact factor: 53.106

Review 10.  Glycosylation as a strategy to improve antibody-based therapeutics.

Authors:  Roy Jefferis
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

View more
  9 in total

1.  Design, construction and in vivo functional assessment of a hinge truncated sFLT01.

Authors:  Fahimeh Zakeri; Hamid Latifi-Navid; Zahra-Soheila Soheili; Mehdi Sadeghi; Seyed Shahriar Arab; Shahram Samiei; Ehsan Ranaei Pirmardan; Sepideh Taghizadeh; Hamid Ahmadieh; Ali Hafezi-Moghadam
Journal:  Gene Ther       Date:  2022-09-16       Impact factor: 4.184

2.  Engineered protease-resistant antibodies with selectable cell-killing functions.

Authors:  Michelle Kinder; Allison R Greenplate; Katharine D Grugan; Keri L Soring; Katharine A Heeringa; Stephen G McCarthy; Gregory Bannish; Meredith Perpetua; Frank Lynch; Robert E Jordan; William R Strohl; Randall J Brezski
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

3.  Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.

Authors:  Ryutaro Asano; Ippei Shimomura; Shota Konno; Akiko Ito; Yosuke Masakari; Ryota Orimo; Shintaro Taki; Kyoko Arai; Hiromi Ogata; Mai Okada; Shozo Furumoto; Masayoshi Onitsuka; Takeshi Omasa; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Mitsuo Umetsu; Izumi Kumagai
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

4.  An anti-TNF-α antibody mimetic to treat ocular inflammation.

Authors:  Hanieh Khalili; Richard W Lee; Peng T Khaw; Steve Brocchini; Andrew D Dick; David A Copland
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

5.  Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance.

Authors:  Saori Suzuki; Hiroaki Annaka; Shota Konno; Izumi Kumagai; Ryutaro Asano
Journal:  Sci Rep       Date:  2018-11-22       Impact factor: 4.379

6.  Proteoform-Resolved FcɤRIIIa Binding Assay for Fab Glycosylated Monoclonal Antibodies Achieved by Affinity Chromatography Mass Spectrometry of Fc Moieties.

Authors:  Steffen Lippold; Simone Nicolardi; Manfred Wuhrer; David Falck
Journal:  Front Chem       Date:  2019-10-24       Impact factor: 5.221

7.  Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.

Authors:  Yang Shen; Lin Zeng; Aiping Zhu; Tim Blanc; Dipa Patel; Anthony Pennello; Amtul Bari; Stanley Ng; Kris Persaud; Yun Kenneth Kang; Paul Balderes; David Surguladze; Sagit Hindi; Qinwei Zhou; Dale L Ludwig; Marshall Snavely
Journal:  MAbs       Date:  2013-04-08       Impact factor: 5.857

8.  An antibody with Fab-constant domains exchanged for a pair of CH3 domains.

Authors:  Gordana Wozniak-Knopp; Gerhard Stadlmayr; Jan Walther Perthold; Katharina Stadlbauer; Mathias Gotsmy; Stefan Becker; Florian Rüker
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

9.  R409K mutation prevents acid-induced aggregation of human IgG4.

Authors:  Hiroshi Namisaki; Seiji Saito; Keiko Hiraishi; Tomoko Haba; Yoshitaka Tanaka; Hideaki Yoshida; Shigeru Iida; Nobuaki Takahashi
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.